Nicola Giuliani

UNVERIFIED PROFILE

Are you Nicola Giuliani?   Register this Author

Register author

Nicola Giuliani

Publications by authors named "Nicola Giuliani"

Are you Nicola Giuliani?   Register this Author

80Publications

-Reads

Predicting and Optimizing Microswimmer Performance from the Hydrodynamics of Its Components: The Relevance of Interactions.

Soft Robot 2018 May 15. Epub 2018 May 15.

MathLab, SISSA-International School for Advanced Studies , Trieste, Italy .

View Article
May 2018

Possible targets to treat myeloma-related osteoclastogenesis.

Expert Rev Hematol 2018 Apr 9;11(4):325-336. Epub 2018 Mar 9.

a Department Medicine and Surgery , University of Parma , Parma , Italy.

View Article
April 2018

The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38.

Immunol Lett 2018 Apr 24. Epub 2018 Apr 24.

Department Medicine and Surgery, University of Parma, 43126 Parma, Italy; Hematology and BMT Center, "Azienda Ospedaliero-Universitaria di Parma", 43126 Parma, Italy. Electronic address:

View Article
April 2018

The Proteasome and Myeloma-Associated Bone Disease.

Calcif Tissue Int 2018 Feb 28;102(2):210-226. Epub 2017 Oct 28.

Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126, Parma, Italy.

View Article
February 2018

A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis.

Case Rep Hematol 2018 31;2018:9840405. Epub 2018 Jan 31.

UO di Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma and Department of Medicine and Surgery, University of Parma, Parma, Italy.

View Article
January 2018

Role of Galectins in Multiple Myeloma.

Int J Mol Sci 2017 Dec 17;18(12). Epub 2017 Dec 17.

Department of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43126 Parma, Italy.

View Article
December 2017

GPNA inhibits the sodium-independent transport system L for neutral amino acids.

Amino Acids 2017 08 17;49(8):1365-1372. Epub 2017 May 17.

Laboratory of General Pathology, Department of Medicine and Surgery, University of Parma, Via Volturno 39, 43125, Parma, Italy.

View Article
August 2017

The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma.

Expert Opin Ther Targets 2017 Mar 18;21(3):231-234. Epub 2017 Jan 18.

b Department of Biomedical , Biotechnological and Translational Sciences, University of Parma , Parma , Italy.

View Article
March 2017

Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.

Mol Med 2016 Oct 13;22. Epub 2016 Oct 13.

Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Torino 10126, Italy.

View Article
October 2016

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.

Biomed Res Int 2015 22;2015:172458. Epub 2015 Oct 22.

Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, 43126 Parma, Italy ; UO di Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, Italy.

View Article
August 2016

The osteoblastic niche in the context of multiple myeloma.

Ann N Y Acad Sci 2015 Jan 25;1335:45-62. Epub 2014 Nov 25.

Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy.

View Article
January 2015

CD38 and bone marrow microenvironment.

Front Biosci (Landmark Ed) 2014 Jan 1;19:152-62. Epub 2014 Jan 1.

Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino Medical School, Via Santena 19, 10126 Torino, Italy.

View Article
January 2014

Angiogenesis and multiple myeloma.

Cancer Microenviron 2011 Dec 7;4(3):325-37. Epub 2011 Jul 7.

Hematology and BMT Center, University of Parma, via Gramsci 14, 43100, Parma, Italy,

View Article
December 2011

Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations.

Am J Hematol 2011 Dec 22;86(12):E64-6. Epub 2011 Sep 22.

Department of Medical Sciences, University of Milano and Hematology 1, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

View Article
December 2011

Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells.

Clin Cancer Res 2011 Nov 31;17(22):6963-70. Epub 2011 Aug 31.

Hematology and Blood and Marrow Transplantation (BMT) Center, University of Parma, Parma, Italy.

View Article
November 2011

Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma.

Clin Cancer Res 2010 Aug 29;16(16):4188-97. Epub 2010 Jun 29.

Department of Experimental and Laboratory Medicine, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

View Article
August 2010

Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.

Exp Hematol 2009 Aug 14;37(8):879-86. Epub 2009 May 14.

Cattedra di Ematologia e CTMO, Azienda Ospedaliero-Universitaria, Parma, Italy.

View Article
August 2009

Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma.

Stem Cells Dev 2007 Dec;16(6):921-30

Institute of Basic Medical Sciences and School of Basic Medicine, Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China.

View Article
December 2007

Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma.

Leuk Lymphoma 2007 Dec;48(12):2323-9

Cattedra di Ematologia e CTMO, Universita Degli Studi di Parma, Parma, Italy.

View Article
December 2007

Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.

Cancer Res 2007 Aug;67(16):7665-74

Hematology and Bone Marrow Transplantation Center, Department of Internal Medicine and Biomedical Science, University of Parma, Parma, Italy.

View Article
August 2007

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.

Blood 2007 Jul 19;110(1):334-8. Epub 2007 Mar 19.

Hematology and Bone Marrow Transplantation Center, Department of Internal Medicine and Biomedical Science, University of Parma, Parma, Italy.

View Article
July 2007

MDR1 polymorphism influences the outcome of multiple myeloma patients.

Br J Haematol 2007 Jun;137(5):454-6

Department of Oncology, Transplants and Advanced Technologies, Section of Hematology, Pisa University, Pisa, Italy.

View Article
June 2007

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

Blood 2006 Dec 17;108(13):3992-6. Epub 2006 Aug 17.

Cattedra e Unità Operativa (UO) di Ematologia-Centro Trapianti Midollo Osseo (CTMO), Università Degli Studi di Parma, Italy.

View Article
December 2006

Targeting pathways mediating bone disease.

Curr Pharm Biotechnol 2006 Dec;7(6):423-9

Hematology and BMT Center, Department of Internal Medicine and Biomedical Science, University of Parma, Italy.

View Article
December 2006

Biology and treatment of multiple myeloma.

Biol Blood Marrow Transplant 2006 Jan;12(1 Suppl 1):81-6

Seràgnoli Institute of Hematology and Medical Oncology, Bologna University, Italy.

View Article
January 2006

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.

Blood 2005 Oct 2;106(7):2472-83. Epub 2005 Jun 2.

Laboratory of Hematology, Hematology and Bone Marrow Transplantation (BMT) Center, Department of Internal Medicine and Biomedical Science, University of Parma, Parma, Italy.

View Article
October 2005

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.

Blood 2005 Aug 5;106(4):1407-14. Epub 2005 May 5.

Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

View Article
August 2005

OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?

Clin Rheumatol 2005 Jun 4;24(3):296-300. Epub 2004 Dec 4.

Dipartimento Osteo-Articolare, Unità Operativa di Reumatologia e Medicina Interna, Azienda Ospedaliera di Parma, Via Gramsci, 14, 43100, Parma, Italy.

View Article
June 2005

Angiogenic switch in multiple myeloma.

Hematology 2004 Oct-Dec;9(5-6):377-81

Chair of Hematology and BMT Center, University of Parma, Parma, Italy.

View Article
April 2005

Angiopoietin-1 and myeloma-induced angiogenesis.

Leuk Lymphoma 2005 Jan;46(1):29-33

Multiple Myeloma Research Unit, Chair of Hematology and BMT Center, University of Parma, Italy.

View Article
January 2005

Update on the pathogenesis of osteolysis in multiple myeloma patients.

Acta Biomed 2004 Dec;75(3):143-52

University of Parma, Parma, Italy.

View Article
December 2004

Angiopoietins expression by human myeloma cells.

Haematologica 2003 Jun;88(6):ELT20; author reply ELT21

Department of Internal Medicine and Biomedical Science, University of Parma, Italy.

View Article
June 2003